A Crohn’s Conundrum: Can the Faecal Calprotectin Level Act as a Sensitive Cut-off to Prevent Unnecessary MRI Small Bowel Scans?
DOI:
https://doi.org/10.17140/ROJ-2-117Keywords:
Crohn’s disease, Magnetic resonance imaging (MRI);, Faecal calprotectinAbstract
Background: Current gastroenterology practice in evaluating those with diarrhoeal symptoms
and a positive faecal calprotectin (CP) is to perform colonoscopy. Colonoscopy however is
limited, in that it cannot exclude disease proximal to the terminal ileum. Therefore, for many
patients not known to have Crohn’s disease, gastroenterologists are often concerned about the
possibility of more proximal small bowel Crohn’s and request an magnetic resonance imaging
(MRI) small bowel scan.
Aims: This is the first study to investigate whether patients with a clinical suspicion of Crohn’s
but with a normal colonoscopy will benefit from MRI in terms of diagnostic evaluation if they
have a CP below the cut-off.
Method: MRI small bowel reports, CP levels and colonoscopy reports were analysed (where
obtainable) from 422 scans at a district general hospital in Stevenage, between 02/04/2015 and
21/07/2017. Eighty-five patients had features suggestive of Crohn’s but had normal colonoscopy
findings. These were divided into those who had a CP above or below 600.
Results: Within 55 patients who had a calprotectin below 600, we report that none (0%) of
these patients were found to have significantly positive findings for Crohn’s on subsequent
MRI. Amongst 30 patients with a positive CP, 8 (26.6%) were found to have active disease on
MRI. The sensitivity of calprotectin was therefore identified to be 100% (95% CI 63.06% to
100%) and the specificity of the test was 71.43 % (95% CI 60% to 81.15%). Negative predictive
value (NPV) was 1.00 and positive predictive value (PPV) was 0.27.
Conclusion: Our study is the first to suggest that in patients with features of Crohn’s who have
a normal colonoscopy, calprotectin performs impressively as a sensitive marker of the presence
of small bowel inflammation on subsequent MRI. Further prospective studies would be needed
to validate a potential approach of using the biomarker as a cut-off to reduce unnecessary MRI
small bowel scans.
References
Gomollón F, Dignass A, Annese V, et al. 3rd European evi-dence-based consensus on the diagnosis and management of crohn’s disease 2016: Part 1: Diagnosis and medical manage-ment. J Crohn’s Colitis. 2017; 11(1): 3-25. doi: 10.1093/ec-co-jcc/jjw168
Sempere GAJ, Martinez Sanjuan V, Medina Chulia E, et al. MRI evaluation of inflammatory activity in Crohn’s disease. AJR Am J Roentgenol. 2005; 184(6): 1829-1835. doi: 10.2214/ ajr.184.6.01841829
Tolan DJM, Greenhalgh R, Zealley IA, Halligan S, Taylor SA. MR enterographic manifestations of small bowel Crohn disease. Radiographics. 2010; 30(2): 367-384. doi: 10.1148/ rg.302095028
Del Vescovo R, Sansoni I, Caviglia R, et al. Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: Differentiation of activity of Crohn’s disease. Abdom Imaging. 2008; 33(4): 417-424. doi: 10.1007/s00261-007-9267-4
Lescut D, Vanco D, Bonnière P, et al. Perioperative endoscopy of the whole small bowel in Crohn’s disease. Gut. 1993; 34(5): 647-649. doi: 10.1136/GUT.34.5.647
Tibble JJ, Teahon KK, Thjodleifsson BB, et al. A simple meth-od for assessing intestinal inflammation in Crohn’s disease. Gut. 2000; 47(4): 506-513. doi: 10.1136/gut.47.4.506
Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin more accurately predicts endoscopic remission of Crohnʼs dis-ease than serological biomarkers evaluated using balloon-as-sisted enteroscopy. Inflamm Bowel Dis. 2017: 1. doi: 10.1097/ MIB.0000000000001202
van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotec-tin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010; 341: c3369. doi: 10.1136/bmj.c3369
Summerton CB, Longlands MG, Wiener K, Shreeve DR. Fae-cal calprotectin: A marker of inflammation throughout the intes-tinal tract. Eur J Gastroenterol Hepatol. 2002; 14(8): 841-845. doi: 10.1097/00042737-200208000-00005
von Roon AC, Karamountzos L, Purkayastha S, et al. Diag-nostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy. Am J Gastroenterol. 2007; 102(4): 803-813. doi: 10.1111/j.1572-0241.2007.01126.x
Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with in-flammatory bowel disease. Scand J Gastroenterol. 2004; 39(10): 1017-1020. doi: 10.1080/00365520410007971
Costa F, Mumolo MG, Bellini M, et al. Role of faecal cal-protectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003; 35(9): 642-647. doi: 10.1016/S1590- 8658(03)00381-5
Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnet-ic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011; 17(5): 1073-1080. doi: 10.1002/ibd.21533
Yoon K, Chang KT, Lee HJ. MRI for Crohn’s dis-ease: Present and future. Biomed Res Int. 2015; 2015. doi: 10.1155/2015/786802
Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in il-eocolonic Crohn’s disease. Gut. 2009; 58(8): 1113-1120. doi: 10.1136/gut.2008.167957
Samuel S, Bruining DH, Loftus E V, et al. Endoscopic skip-ping of the distal terminal ileum in Crohn’s disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepa-tol. 2012; 10(11): 1253-1259. doi: 10.1016/j.cgh.2012.03.026
Lalkhen AG, McCluskey A. Clinical tests: Sensitivity and specificity. Contin Educ Anaesth Crit Care Pain. 2008; 8(6): 221-223. doi: 10.1093/bjaceaccp/mkn041
RCR. RCR Submission to HEE workforce planning round 2015-16. 2015. Web site. https://www.rcr.ac.uk/sites/default/ files/documents/hee_evidence_2015-16_clinical_radiology.pdf. Accessed September 19, 2017.
Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-re-fractory Crohn’s disease: Real world experience from a mul-ticentre cohort. Aliment Pharmacol Ther. 2017; 45(9): 1232- 1243. doi: 10.1111/apt.14016
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Radiology (ROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.